ID
31306
Description
Study ID: 104505 Clinical Study ID: BEX104505 Study Title: Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00950755 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin Any adverse experience is defined as a new or worsening pre-existing medical condition or complication occurring while on study, regardless of its perceived relationship to the drug. Please record all adverse experiences from the time of study entry through the Week 13 visit.
Mots-clés
Versions (1)
- 12/08/2018 12/08/2018 -
Détendeur de droits
see clinicaltrials.gov
Téléchargé le
12 août 2018
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Iodine 131 B1 Antibody for B-Cell Lymphomas NCT00950755
Adverse Experiences
- StudyEvent: ODM
Description
Adverse Experiences
Alias
- UMLS CUI-1
- C0877248
Description
Adverse Event; Number
Type de données
integer
Alias
- UMLS CUI [1,1]
- C0877248
- UMLS CUI [1,2]
- C0237753
Description
Adverse Event
Type de données
text
Alias
- UMLS CUI [1]
- C0877248
Description
Adverse Event; CTC grade
Type de données
text
Alias
- UMLS CUI [1]
- C2985911
Description
Adverse event, serious
Type de données
boolean
Alias
- UMLS CUI [1]
- C1519255
Description
Adverse event; start date
Type de données
date
Alias
- UMLS CUI [1]
- C2697888
Description
Adverse event; end date
Type de données
date
Alias
- UMLS CUI [1]
- C2697886
Description
Adverse event; frequency
Type de données
text
Alias
- UMLS CUI [1,1]
- C0877248
- UMLS CUI [1,2]
- C0439603
Description
Adverse event; Therapeutic Measures; Drugs
Type de données
text
Alias
- UMLS CUI [1,1]
- C0877248
- UMLS CUI [1,2]
- C0087111
- UMLS CUI [1,3]
- C0013227
Description
Adverse event; Therapeutic Measures; Other
Type de données
text
Alias
- UMLS CUI [1,1]
- C0877248
- UMLS CUI [1,2]
- C0087111
- UMLS CUI [1,3]
- C0205394
Description
Adverse event; Therapeutic Measures; Other; Specification
Type de données
text
Alias
- UMLS CUI [1,1]
- C0877248
- UMLS CUI [1,2]
- C0087111
- UMLS CUI [1,3]
- C0205394
- UMLS CUI [1,4]
- C2348235
Description
Adverse event; Outcome
Type de données
text
Alias
- UMLS CUI [1]
- C1705586
Description
Adverse event; Relationship; Drug
Type de données
text
Alias
- UMLS CUI [1,1]
- C0877248
- UMLS CUI [1,2]
- C0439849
- UMLS CUI [1,3]
- C0013227
Description
Adverse event; Relationship; Disease
Type de données
text
Alias
- UMLS CUI [1,1]
- C0877248
- UMLS CUI [1,2]
- C0439849
- UMLS CUI [1,3]
- C0012634
Similar models
Adverse Experiences
- StudyEvent: ODM
C0600091 (UMLS CUI [1,2])
C0237753 (UMLS CUI [1,2])
C0439603 (UMLS CUI [1,2])
C0087111 (UMLS CUI [1,2])
C0013227 (UMLS CUI [1,3])
C0087111 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,3])
C0087111 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,3])
C2348235 (UMLS CUI [1,4])
C0439849 (UMLS CUI [1,2])
C0013227 (UMLS CUI [1,3])
C0439849 (UMLS CUI [1,2])
C0012634 (UMLS CUI [1,3])